No significant difference seen in urodynamic testing results between TPTNS and rTMS groups
WEDNESDAY, May 7, 2025 (HealthDay News) — For female patients with multiple sclerosis (MS), transcutaneous posterior tibial nerve stimulation (TPTNS) and repetitive transcranial magnetic stimulation (rTMS) are comparable for neurogenic overactive bladder symptoms, according to a study published online April 11 in Neurodegenerative Disease Management.
Pınar Atak Çakir, from Istanbul Medipol University, and colleagues randomly assigned 16 female patients with MS with neurogenic overactive bladder to receive TPTNS or rTMS for a pilot study. Treatments were applied for a total of 10 sessions over two consecutive weeks.
The researchers observed no significant change within and between the TPTNS and rTMS groups in urodynamic parameters. Significant improvement was seen in nocturia frequency in the TPTNS group compared with the rTMS group based on an analysis of parameters from a three-day voiding diary. There were no significant between-group changes seen in Overactive Bladder Questionnaire-V8, Incontinence Severity Index, or Incontinence Quality of Life Scale parameters.
“The TPTNS and rTMS methods we employed for the treatment of neurogenic overactive bladder are advantageous in that they have no side effects and are easy to apply, and they are suitable treatment options for female patients with MS,” the authors write.
Abstract/Full Text (subscription or payment may be required)
Extreme Heat Linked to 33 Clinically Reportable Diagnoses 
MS-Related Mortality Rates Highest in Non-Hispanic Blacks 
Rituximab Noninferior to Ocrelizumab for Newly Diagnosed Relapsing MS 
Adenotonsillectomy Linked to Increased Odds of Pediatric-Onset MS 
Adenotonsillectomy Tied to Increase in Respiratory Tract Infections in Children 
Robotic Arm-Assisted TKR Offers Similar Outcome to Conventional TKR 
Preoperative Chemo + Immunotherapy Combo Shrinks Head, Neck Cancer Tumors 
Safety Intervention Reduces Incidence of Postoperative Endophthalmitis 
